阿立哌唑、利培酮及氯丙嗪对精神分裂症患者疗效及认知功能的影响分析

Aripiprazole,Risperidone and Chlorpromazine on the efficacy and cognitive function in patients with schizophrenia

目的:探讨阿立哌唑、利培酮及氯丙嗪对精神分裂症患者的临床疗效,分析其对认知功能的影响。方法:选取我院2009年8月～2011年8月收治的经CCMD-3确诊的118例精神分裂症患者,分为阿立哌唑组40例、利培酮组40例和氯丙嗪组38例进行治疗,8周后判定临床疗效和认知功能。结果:三组患者在治疗前后PANSS总分及各子项目得分上差异均无统计学意义(P>0.05);但阿立哌唑组和利培酮组在治疗8周后WMS、MMSE及WCST各项目评分较治疗前有显著改善(P<0.01),而氯丙嗪组治疗前后各项目评分无显著性差异(P>0.05)。结论:阿立哌唑、利培酮和氯丙嗪对精神分裂症患者作用明显,疗效相当,阿立哌唑和利培酮对患者的认知功能改善优于氯丙嗪(氯丙嗪无效),且阿立哌唑的不良反应少,值得进一步研究应用。

Objective：To study the Aripiprazole, Risperidone and Chlorpromazine on the clinical efficacy of schizophrenic pa- tients to analyze their influence on cognitive function. Methods：A hospital from August in 2009 to August 2011 were confirmed by the CCMD -3, 118 cases of patients with schizophrenia were divided into 40 eases of the Aripiprazole group, 40 eases of Rispefidone group and 38 cases of chlorpromazine group, 118 patients treated after eight weeks to determine the clinical efficacy and cognitive func- tion. Results： Three groups of patients before and after treatment PANSS total scores and sub - project score differences were not statis- tically significant （ P 〉 0.05 ） ; After 8 weeks of treatment , Aripiprazole group and Risperidone group with the WMS, MMSE and WCST of the project score were significantly improved （P 〈 0.01 ） before treatment, each item in the chlorpromazine group before and after treatment was no significant difference （ P 〉 0.05 ）. Conclusions ： Aripiprazole, Risperidone and Chlorpromazine with schizophre- nia is considerable efficacy, Aripiprazole and Risperidone in improving the cognitive function of patients are better than chlorpromazine （invalid）, and A legislation Prazosin adverse reactions are less worthy of further research and application.